Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Garry Nolan

Yury Goltsev

Nikolay Samusik

Akoya Biosciences, Inc.

Deciphex provides digital pathology solutions that leverage AI to enhance pathology service delivery and improve diagnostic turnaround times.

Donal O'Shea

Mark Gregson

Mairin Rafferty

Deciphex

Takara Bio USA, Inc. provides kits, reagents, instruments, and services that help researchers explore questions about gene discovery, regulation, and function.

Takara Bio USA, Inc.

Value Today provides information on the top 1,000 companies globally based on market capitalization, including their financial metrics and company profiles.

Value Today

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. 

Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels, PhenoCycler®, PhenoImager® Fusion, and PhenoImager HT Instruments.

View our open job descriptions: www.akoyabio.com/careers

Follow us on Twitter: www.twitter.com/AkoyaBio   

Subscribe to our YouTube channel: www.youtube.com/c/AkoyaBiosciences 

Innovatus Capital Partners

Telegraph Hill Partners

Piper Jaffray Merchant Banking

Thomas Schnettler

We are excited to welcome Crown Bioscience as an Akoya-qualified service provider! Headquartered in San Diego, CA, Crown Bioscience aims to support drug discovery through translational research across oncology and immuno-oncology.

By joining our Contract Research Organization Network, Crown Bioscience will utilize Akoya's Phenomager HT platform to offer advanced multispectral imaging technology, easily integrated into high-throughput workflows to accommodate projects regardless of scale.

Explore Crown Bioscience's digital pathology technologies: https://bit.ly/3T0ALxY

#oncology #immunooncology #drugdiscovery #phenoimager #crownbioscience

This groundbreaking study, published in Nature using our PhenoImager HT platform, offers a fresh perspective on the pathology and heterogeneity of rheumatoid arthritis. The findings hold promise for developing innovative targeted treatments for patients with this condition. 

🙌 Kudos to the authors for their valuable contribution to understanding this debilitating, autoimmune disease without a cure!

#FridayRead #PhenoImager #AkoyaInAction #SpatialBiology #RheumatoidArthritis

Join us at the Cancer Neuroscience Symposium at the MD Anderson Cancer Center in Houston, Texas!

The Akoya team will be there today and tomorrow and will be happy to discuss how our spatial biology solutions are making a difference in neuroscience and cancer research. 

Not attending? Explore our solutions on our website: https://bit.ly/47GvLFB

#SpatialBiology #Neuroscience #MDAnderson #CancerResearch #Immunology

Dr. Tom Lund and his team at the Integrated Pathology Unit (IPU) in London have consistently used our instruments, with the PhenoImager HT serving as a central resource in their laboratory.

The IPU, a collaborative effort between The Institute of Cancer Research and the Royal Marsden Hospital, is crucial in bridging clinical, translational, and basic research. Dr. Lund attributes the IPU's flexibility to their tissue-agnostic Akoya technology, which requires minimal tissue-specific optimization, allowing seamless adaptation to diverse research requirements.

We are thankful for Dr. Lund's ongoing support of our technology. We are excited to witness his lab's advancements in further understanding and treating cancer through multiplex immunofluorescence.

#spatialbiology #digitalpathology #multiplex #phenoimager SelectScience®

📢 Tomorrow is part 1 of a 2-part webinar series on fusing single-cell genomics and spatial proteomics with MaxFuse!

Hear Garry Nolan, Ph.D., discuss MaxFuse, a new AI algorithm that provides reliable, fast, and cost-effective integration of spatial proteomic data with single-cell transcriptomic and epigenomic datasets. 

This webinar will be offered at two different times on Feb 28th; attendees can join at 3 AM PT/6 AM ET/12 PM CET or 9 AM PT/12 PM ET/6 PM CET. 

Hope to see you there!

#spatialbiology #spatialproteomics #maxfuse #singlecell #genomics Genetic Engineering & Biotechnology News 

Metric
Company Name	Akoya Biosciences, Inc.	Deciphex	Takara Bio USA, Inc.	Value Today
Symbol	AKYA
MSH ID	COM:AKOYABIO	COM:DECIPHEX	COM:TAKARABIO	TODAY:VALUE
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Commercial & Professional Services
Industry	Medical - Instruments & Supplies	Medical Technology	Biotechnology	Financial Services
Country	US	IE	US	US
Stage		Debt Financing
Employee Count	330	118
Website	akoyabio.com	deciphex.com	takarabio.com	value.today
LinkedIn	akoya-biosciences-inc
Founders

Metric
Market Cap	102.72M
Enterprise Value
Monthly Web Traffic	14.40K	1.24K
Web Traffic Growth	0.17	-0.17
Valuation
Raised Capital		10.55M

Metric
Revenue	96.63M
Revenue (LTM)
Revenue (NTM)
Gross Profit	48.24M
EBITDA	-47.14M
Operating Income	-56.03M
Net Income	-63.32M
EPS	-1.43
Diluted EPS	-1.43
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.56
Operating Profit Margin	-0.52
EBITDA Margin	-0.49
Net Profit Margin	-0.65
Return on Equity	-1.10
Return on Assets	-0.35
Return on Capital Employed	-0.39

COM:AKOYABIO

Akoya Biosciences, Inc.

Last Close

2.12

22/11 21:00

Market Cap

102.72M

Beta: -

Volume Today

81.11K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-3.80
P/B Ratio	4.37
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.49
EV Multiple	-0.46

Metric
Days Sales Outstanding	64.30
Days Payables Outstanding	231.01
Days Inventory Outstanding	218.46
Operating Cycle	283.28
Cash Conversion Cycle	197.07
Asset Turnover	0.65

Metric
Operating Cash Flow	-50.90M
Free Cash Flow	-54.55M
Cash Flow to Debt	-0.51
Operating Cash Flow/Sales	-0.43
Free Cash Flow Yield	-0.22

Metric
Cash & Equivalents	83.13M
Accounts Receivable	-7.26M
Inventory	17.88M
Goodwill	18.26M
Debt to Capitalization	0.78
Debt to Assets	0.42
Current Ratio	3.29
Quick Ratio	2.83

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.11
R&D to Revenue	0.26
SG&A to Revenue